Ekf Diagnostics Investors - EKF

Ekf Diagnostics Investors - EKF

Best deals to access real time data!
Monthly Subscription
for only
Level 2 Basic
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type
Ekf Diagnostics Holdings Plc EKF London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
-0.60 -0.79% 75.60 16:35:27
Open Price Low Price High Price Close Price Previous Close
75.20 73.80 75.60 75.60 76.20
more quote information »
Industry Sector

Top Investor Posts

wan: No specific insight yet that I can recall, aside from indicating a target of one investment per year and one floatation per year. And according to the Growth Strategy, EKF continue to be in conversations with MSIP over future initiatives and they will look to update investors at the Interim Statement in September 2021 (page 13) - hTTps://www.ekfdiagnostics.com/res/EKF%20Investor%20Presentation%20June%202021%20Growth%20strategy%202021-2024.ppt.pdf
gocanes: Investor presentation this Thursday @ 10am - https://investegate.co.uk/genincode-uk-ltd/rns/investor-presentation/202107190700085854F/ Matthew Walls, CEO and Paul Foulger, CFO will provide a live investor presentation via the Investor Meet Company platform at 10am BST on Thursday, 22 July 2021. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet GENinCode plc via:hxxps://www.investormeetcompany.com/genincode-plc/register-investor
wan: In my view, we should be aware, but also be careful how much to read into the following article regarding Abbotts downgrade to earnings from, and in particular, the faster than expected decline in 'rapid' COVID-19 testing demand - Abbott's COVID-19 testing surprise suggests demand softening faster than sector forecast Published June 2, 2021 Abbott CEO Robert Ford told investors Tuesday it had no way of knowing in April when it reported first-quarter earnings that market dynamics would change so dramatically in subsequent weeks. At that time, Ford said Abbott was seeing coronavirus case rates holding steady in the U.S. and other major developed countries. However, in May, the test maker experienced a "sudden" and fundamental drop-off in demand for COVID-19 testing, particularly for screening and surveillance with rapid testing. "While we've always said the demand for COVID testing sales would eventually work its way to a flu-like level, we couldn't have anticipated what has occurred over the past several weeks," Ford told investors on Tuesday's conference call. Abbott now forecasts about $4 billion to $4.5 billion in COVID-19 testing sales in 2021, including second-quarter sales of around $1.1 billion. The company previously forecasted about $6.5 billion to $7 billion in coronavirus test sales on its fourth-quarter earnings call in late January. Looking beyond 2021, SVB Leerink analysts Tuesday wrote that "given that the new guidelines might eliminate the end-user demand effectively" they slashed their 2022 Abbott COVID-19 testing revenue estimate of about $3.5 billion to $4 billion to approximately $300 million. Jefferies analysts also now forecast $300 million of overall COVID-19 testing in 2022 based on their assumption of a "faster drop to a normal-like seasonal flu trend." News of the plummet in test demand and the company’s decision to cut its 2021 outlook sent Abbott's stock down more than 9% yesterday, while Quidel's share price dropped more than 7% in reaction. Full story - hTTps://www.medtechdive.com/news/abbotts-covid-19-testing-surprise-suggests-demand-softening-faster-than-se/601127/ Rapid testing of the type Abbott is particularly referring to is not related to PCR testing, and such rapid testing is not dependant on a specimen collection device e.g. such as that used in test kits, pooled samples and sequencing etc, which EKF manufacture and supply.
wan: The following springs to mind - “You can please some of the people all of the time, you can please all of the people some of the time, but you can't please all of the people all of the time." and that sums up life in virtually all situations! In other words, nothing is going to be perfection, but EKF do a damn good job in rewarding all their investors and generating further value via investment/spin-out opportunities. And it's perhaps easy to overlook the fact that we also need new investors to view EKF as being an attractive investment. Let's keep firmly in mind, the degree of shareholder value already created by our very focused and forward-thinking management team and the tax efficient delivery of that value creation via in-specie dividends and spin-out, especially into 'private investors' ISA's and SIPPS. Not to mention the long-term growth plan now being put into action, which should drive earnings and create additional long-term value, along with Julian Baines new role, which will see him focus on delivering further value from the Company’s relationship with Mount Sinai Innovation Partners, which in my opinion provides an overall investment proposition that should make EKF shares a compelling addition to investment portfolios, as well as instilling the rationale to hold long term (and potentially add). Whilst I am sure further lessons will have been learnt/taken onboard etc, by the same token, it would be a shame if enabling private EKF investors was seen as being too complicated, especially if that caused too much by way of criticism (and possibly via unjustified disappointment), albeit I am sure constructive criticism will be welcome. In this regard, I am still in active discussions with Barclays, and I am sure resolving some of the platform/nominee issues could alleviate some of the criticisms, and no doubt disappointment, especially for those preferring to have utilised their ISA's and SIPP's.
wan: I wrote the following a few weeks ago for the EKF thread (for obvious reasons), but I never got around to posting it. However, I posted it on the Renalytix thread this morning as I thought it had at least some relevance there. And seeing as it was intended for here and it mentions EKF, I thought I would post it here too - Maybe the following personal story is of relevance? Many years ago, when I was a relatively naive investor (and I am still learning today!), I learnt what I later believed to be an important lesson. I owned a share that had risen circa 7-fold to circa £6, which at the time I still saw no reason to sell as the prospects still appeared to be very good to me. However, the CEO sold a relatively large chunk of stock at around the same price (but still held shares), which at the time effectively undermined my rationale to continue to hold and subsequently it shook me (and quite a few other private investors) out the stock entirely, as naively I couldn't understand why he would sell if the prospects were so good? Anyway, I banked a substantial profit. Post the CEO's sale (and mine) the shares continued to perform quite strongly and eventually the company was bought out at £18 per share. The lesson was that the CEO had sold into strong investor and institutional investor demand, as well as there being the usual personal and regulatory timing matters etc. So, certain insider selling at certain times e.g. when the prospects are good (and guided), and demand is high, can be instructive in perhaps more ways than first impressions imply. Some would say that it's never wrong to take a profit, and that I should have sold only part of my holding, yes may be, and hindsight is a wonderful thing, but I believe I did learn from that experience. My main thrust is that taking a profit can be wrong, just as taking a loss can be right, and there is probably no absolute catch-all practice that is guaranteed to work. But I would suggest that the managements track record in delivering value to shareholders is as good as anything, and EKF and Renalytix investors have had that delivered in spades! Importantly, there are strong indications to suggest that there is more growth and value creation to come. Readers will get my drift, but investors should of course make up the own minds and arrive at their own conclusions when making investment decisions.
wan: Soon after posting my tribulations on here, the document from Barclays arrived, and after intense interrogation regarding the bank transfer, I was able to complete the application process (perhaps they read this thread). I too had interaction with corporate actions at Barclays yesterday. As Boadicea implies, from what I can tell and from past experience, one of the main issues is differentiating which clients are not US citizens (regulation S from memory) and therefore enabling a UK citizen/investor to take part. However, Barclays Smart Investor are apparently not able to do this, which is almost unbelievable given what information they hold on their clients. After my interaction yesterday, it will get discussed internally 'again' at Smart Investor, but that is exactly what they said last time regarding my Renalytix and Verici fiasco's! With other brokers clearly able to enable investors to take part, apparently seamlessly, and given Barclays lack of effort and commitment in implementing/updating their systems and procedures etc, 'Smart Investors' might look to consider transferring to those platforms that delivered and/or responded effectively to their clients requests.
wan: I decided I would remind myself what Chris Mills said in an interview on the 17th November 2020 regarding EKF when the share price was 64p. In short, there were a number of elements he regarded as being in the price for free at 64p, albeit he did state at some point they would have to sell some shares, as EKF would be too big a percentage of their portfolio, "but it sure ain't at this price" (64p). He also said EKF had "life way beyond COVID". Interview (EKF at 15mins 40 seconds in) hTTps://www.voxmarkets.co.uk/media/5fb3dd97bc74c922485f4f5b/ So, as discussed on here, we probably know why Chris Mills sold some at 80p, but given his remarks regarding the price at 64p, investors will no doubt be wondering where the floor is. So, it will thus be interesting to see if we are there yet, but it is perhaps worth recalling that the directors are incentivised in the event that the Company is acquired by a third party. However, clearly Chris Mills expects more that 64p for their EKF shares, believing there are elements included in the price for free and plenty of growth to go for too beyond COVID, which apparently we will be updated on. An exit is not something I would normally highlight, nor indeed promote ("not at this price"), but there is currently a lot of M&A in our sector. To be clear, an exit is currently not what I am wishing for though, but I do wonder whether some form of change is afoot. Currently, I see more reasons to buy than sell, but investors should of course make up their own minds when making investment decisions etc.
wan: As indicated by the CEO, Trellus will not be the last value creation to come out of the EKF/Mount Sinai partnership. And although EKF will also be a cash dividend payer, the spinout opportunities (and ultimately the best use of EKF 'growing' cash pile) will return greater value to investors. Even like those of us who follow EKF closely, we only have the track record to go by, and in this regard Renalytix delivered circa 23p to patient EKF investors and then went onto deliver a lot more, including Verici (and I suspect there is more to come from both of these). I firmly believe Trellus will follow a similar path in terms of delivery to EKF investors. And I am sure most investors are fully behind the management with regard to this value creation policy. What we don't know is what's coming next in terms of potential spinouts, but only the patient investors will find out and ultimately realize the benefit. In the meantime, the core business continues to advance and grow, as do their relationships, which are now extending further.
wan: ESG investing is becoming increasingly popular, with investors pouring money into ESG funds. So, I was interested to note in the IC that EKF feature in the Top ESG Fund Managers' Favourite UK Shares as of 02/12/2020 FUND BEST IDEAS: UK SUSTAINABLE - hTTps://www.investorschronicle.co.uk/tips-ideas/2020/12/02/esg-fund-managers-favourite-uk-shares/ Only one fund is registered (over half of the list has one ESG fund invested) and is based on a funds top 5 holdings (source: Morningstar), but given the increasing interest in the ESG sector, that leaves room for further interest/investment - The Big Theme December 3 2020 The best regional ESG funds By Dave Baxter The explosion of the ESG industry means investors have more fund choices Regional equity fund options are increasing You must first decide what type of ESG approach you want to take Funds that invest according to environmental, social and governance (ESG) principles have proved their worth, with a commendable performance during the sell-off earlier this year. They are also becoming increasingly popular with investors and appear to have entered the mainstream. Full story - hTTps://www.investorschronicle.co.uk/funds-etfs/2020/12/03/the-best-regional-esg-funds/
wan: Readers will already appreciate the dividend that's locked in for December, but there is potentially a lot more than just this cash dividend and future cash dividends. EKF's investment in Trellus Health also has potential to reward patient investors with a dividend in specie in early 2021. So, no doubt a question of what Trellus Health might be worth is probably already featuring in some investors minds, but ultimately this will be determined by market soundings and an initial public offering - hTTps://www.ekfdiagnostics.com/strategic-investment.html The following article adds further to some of my previous posts on the subject of digital health, and indicates a very strong level of investor interest in the sector, which implies there is a very exciting commercial opportunity for Trellus Health - Digital health funding this year already at record high $9.4B, Rock Health says PUBLISHED Oct. 8, 2020 Dive Brief: This year has already shattered digital health funding records, with $9.4 billion raised so far through the third quarter, according to a new report from Rock Health. That's already surpassed the previous record for most dollars raised in a year: $8.2 billion in 2018. The average deal size in 2020 has been $30.2 million, also a record — and about 1.5 times larger than the average of $19.7 million last year, as the pandemic drives sustained consumer interest in digital health and investors funnel more dollars into the sector. Megadeals have skyrocketed, with 24 digital health companies raising deals of $100 million or more through the third quarter, mostly concentrated in telehealth, R&D services and fitness and wellness. In that category, Zwift had the largest funding round with $450 million raised in a Series C. Dive Insight: As it becomes more clear that new realities brought on by the pandemic won't be short-lived, investors are pouring money into digital health — one of the few sectors that's actually benefited from COVID-19. In the third quarter, U.S.-based startups raised $4 billion, and each prior quarter saw at least $2.4 billion raised. Rock Health said the industry is "just on the cusp" of the momentum from unprecedented demand among consumers. "As the pandemic continues to unfold, we are eager to see the industry come together to cement advancements already made this year, and continue on this trajectory," the report says. The analysis jibes with others on digital health funding and speakers at CB Insights' conference last month. Analysts there noted particular interest in mental health platforms as people have reporting rising anxiety and depression amid the pandemic. Full story - hTTps://www.medtechdive.com/news/digital-health-funding-this-year-already-at-record-high-94b-rock-health/586680/
ADVFN Advertorial
Your Recent History
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210729 05:39:31